RE: Short Term Key Stategic Priorities6 May 2024 17:11
Alongside the CFO , I also question the Chairman’s judgement.
Whilst Dr Coughlin has impressive scientific and clinical experience, it’s her business skills that will now come under scrutiny. A CEO at CytoImmune which lasted less than 2 years isn’t a ringing endorsement. Would have preferred she retained her clinical role but maybe few external candidates were that attracted, so rather than wait EF decided upon a hasty solution with AS probably setting the deadline. Hence now acknowledges more weight is still needed .